We are live on ! Find out more
IMDX

Insight Molecular Diagnostics
IMDX

33 hedge funds and large institutions have $22.5M invested in Insight Molecular Diagnostics in 2017 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 10 increasing their positions, 2 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

400% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 2

250% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 2

3% more funds holding

Funds holding: 32 → 33 (+1)

2% more capital invested

Capital invested by funds: $22M → $22.5M (+$437K)

0.1% more ownership

Funds ownership: 0.54% → 0.64% (+0.1%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
33
Holders Change
+1
Holders Change %
+3.13%
% of All Funds
0.82%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
7
Increased
10
Reduced
2
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BC
Broadwood Capital
New York
+$2.45M
2
AG
Artal Group
Luxembourg
+$496K
3
BlackRock
BlackRock
New York
+$471K
4
BCM
Bridgeway Capital Management
Texas
+$260K
5
Goldman Sachs
Goldman Sachs
New York
+$212K

Top Sellers

Rank Fund Capital Flow
1
ECM
Elgethun Capital Management
South Dakota
-$5K
2
MTWSIF
Mivtachim The Workers Social Insurance Fund
Israel
-$4K
3
UBS Group
UBS Group
Switzerland
-$3.46K
4
Bank of America
Bank of America
North Carolina
-$1.16K
Name Holding Trade Value Shares
Change 		Change in
Stake
BC
1
Broadwood Capital
New York
$18.2M +$2.45M +21,250 +16%
AG
2
Artal Group
Luxembourg
$893K +$496K +4,295 +134%
BCM
3
Bridgeway Capital Management
Texas
$866K +$260K +2,250 +45%
Vanguard Group
4
Vanguard Group
Pennsylvania
$584K +$5.2K +45 +0.9%
MHP
5
Manatuck Hill Partners
Connecticut
$500K – – –
BlackRock
6
BlackRock
New York
$485K +$471K +4,075 New
Goldman Sachs
7
Goldman Sachs
New York
$219K +$212K +1,838 New
DWM
8
Destination Wealth Management
California
$176K – – –
Millennium Management
9
Millennium Management
New York
$157K +$152K +1,317 New
FM
10
Family Management
New York
$97K +$25.2K +218 +36%
Geode Capital Management
11
Geode Capital Management
Massachusetts
$89K – – –
Susquehanna International Group
12
Susquehanna International Group
Pennsylvania
$74K +$72.2K +625 New
Bank of New York Mellon
13
Bank of New York Mellon
New York
$63K +$61.1K +529 New
PNC Financial Services Group
14
PNC Financial Services Group
Pennsylvania
$24K – – –
Morgan Stanley
15
Morgan Stanley
New York
$19K +$12K +104 +182%
Manulife (Manufacturers Life Insurance)
16
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$6K – – –
Barclays
17
Barclays
United Kingdom
$6K +$6.12K +53 New
CFA
18
Carroll Financial Associates
North Carolina
$5K – – –
TRCT
19
Tower Research Capital (TRC)
New York
$4K +$4.16K +36 New
Deutsche Bank
20
Deutsche Bank
Germany
$4K +$4.5K +39 +3,900%
Royal Bank of Canada
21
Royal Bank of Canada
Ontario, Canada
$3K +$1.85K +16 +133%
Bank of America
22
Bank of America
North Carolina
$2K -$1.16K -10 -43%
MA
23
MUFG Americas
New York
$2K – – –
UBS Group
24
UBS Group
Switzerland
$1K -$3.46K -30 -86%
Creative Planning
25
Creative Planning
Kansas
$1K – – –
1
2

IMDX Hedge Fund Activity: Q1 2017 in Review

33 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Insight Molecular Diagnostics (IMDX) for Q1 2017, worth a combined $22.5M — up 2% from $22M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new IMDX positions and 2 closed out — a net gain of 5 holders — while 10 added to existing stakes and 2 trimmed.

The largest buyer was Broadwood Capital, adding an estimated $2.45M. The largest seller was Elgethun Capital Management, exiting entirely with an estimated $5K sold.

  • 33 institutional investors held Insight Molecular Diagnostics (IMDX) as of Q1 2017, up from 32 in Q4 2016.
  • Funds reported $22.5M of Insight Molecular Diagnostics stock for Q1 2017, up 2% quarter-over-quarter.
  • 7 funds opened new Insight Molecular Diagnostics positions in Q1 2017 and 2 closed out, a net change of +5 holders.
  • The largest Insight Molecular Diagnostics buyer in Q1 2017 was Broadwood Capital, an estimated $2.45M added.
  • The largest Insight Molecular Diagnostics seller in Q1 2017 was Elgethun Capital Management, an estimated $5K sold.

Based on aggregated 13F filings for Q1 2017.